Platelet aggregation inhibitors

From Citizendium, the Citizens' Compendium

Revision as of 02:53, 22 October 2009 by Robert Badgett (Talk | contribs)
(diff) ←Older revision | Current revision (diff) | Newer revision→ (diff)
Jump to: navigation, search


This article is a stub and thus not approved.
Main Article
Talk
Related Articles  [?]
Bibliography  [?]
External Links  [?]
 
http://en.citizendium.org/wiki?title=Platelet_aggregation_inhibitors&printable=yes
This is a draft article, under development and not meant to be cited but you can help to improve it. These unapproved articles are subject to a disclaimer.

Platelet aggregation inhibitors, also called antiplatelet drugs, are "drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system."[1]

Contents

Classification

Adenosine diphosphate (ADP) blocker

This includes dipyrimadole.

Cyclooxygenase-1 blockers

Cyclooxygenase-1 blockers include aspirin.

Glycoprotein IIb/IIIa inhibitors

Inhibitors of the platelet glycoprotein GPIIb-IIIa complex include eptifibatide, tirofiban, and the monoclonal antibody abciximab.

Thienopyridines

Thienopyridines include clopidogrel, ticlopidine, and the prodrug prasugrel.

References

  1. ↑ Anonymous, (2009) Platelet aggregation inhibitors (English). Medical Subject Headings. U.S. National Library of Medicine.
Retrieved from "http://en.citizendium.org/wiki/Platelet_aggregation_inhibitors"
Views
Personal tools